NY-CELONIS
Celonis , the global leader in execution management, and Nokia today announced a collaboration to develop and create new standards of excellence across multiple business processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005675/en/
As part of the collaboration, Nokia will leverage company-wide deployment of the Celonis® Execution Management System™ (EMS® ). Nokia also plans to develop Execution Apps, and to make these publicly available on the Celonis EMS Store .
Marco Wirén, CFO at Nokia, commented: “With our partnership with Celonis, we are focusing on driving digital process transformation right across Nokia through continuous improvement. This includes enterprise-wide enhancements to automation levels, transparency, accountability, simplicity and cost-efficiency.”
Nokia first initiated a Celonis pilot program in November 2020 covering processes for Order to Invoice, Source to Pay and Accounts Payable. The initial value identified convinced Nokia to expand its use of Celonis across the company. In a company-wide rollout, Nokia is now implementing Celonis' Accounts Receivable , Accounts Payable and Order Management Execution Apps . These empower business users to apply data and intelligence to their processes without swapping out or changing underlying transaction systems.
Miguel Milano, Chief Revenue Officer and Co-Owner of Celonis, commented: “We intend to make Nokia a lighthouse Celonis EMS client. Our vision is that the process improvements we create with Nokia as part of its digital transformation will become benchmarks for business users across multiple industries. Both companies are committed to achieving this, and making the apps resulting from our collaboration available on the Celonis EMS Store. These will be pre-built, user-centric apps that address specific user needs and can be implemented quickly, confidently and effectively.”
Nokia CFO Marco Wirén noted: “Sharing our best practices by making these apps available on the Celonis EMS Store is part of Nokia’s commitment to innovation and technology leadership. In the same way we create value with intellectual property and long-term research at our award-winning Nokia Bell Labs, we intend that the Execution Apps we are creating on the Celonis platform will become recognized global standards.”
About Celonis
Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.
© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005675/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release
The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove
Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 22:30:00 CET | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
